Reduction of Inducible Nitric Oxide Synthase via Angiotensin Receptor Blocker Prevents the Oxidative Retinal Damage in Diabetic Hypertensive Rats

Autor(es)

Silva, Kamila C. ^[1] ; Rosales, Mariana A. B. ^[1] ; Lopes de Faria, Jose B. ^[1] ; Lopes de Faria, Jacqueline M. ^[1]

Afiliação do(s) autor(es)

^[1] State Univ Campinas Unicamp, Fac Med Sci FCM, Renal Pathophysiol Lab, Campinas, SP - Brazil

• Tipo de documento: Artigo Científico
• Fonte: CURRENT EYE RESEARCH; v. 35, n. 6, p. 519-528, JUN 2010.
• Citações Web of Science: 11

Resumo

Purpose: To investigate if nitric oxide (NO) system contributes to the beneficial effect of angiotensin II type 1 receptor (AT 1) blocker losartan in the retina of diabetic spontaneously hypertensive rats (SHR). Methods: Diabetic SHR were randomized to receive oral treatment with losartan (DM-SHRLos). After 20 days, the rats were euthanized and the retinas collected. Results: Diabetic SHR rats exhibited a significant increase in glial fibrillary acidic protein (GFAP) and decrease in occludin, markers of early diabetic retinopathy (DR). The oxidative status, evaluated by NO end-products (NO(x)(-)) levels along with the antioxidative system superoxide dismutase, revealed an accentuated imbalance in favor to oxidants in DM-SHR leading to a higher tyrosine nitration and DNA damage. The inducible NO synthase (iNOS) was also elevated in DM-SHR rats. The treatment with losartan ameliorated all of the above alterations. Conclusions: Oral treatment with losartan reduces iNOS expression and reestablishes the redox status, thus ameliorating the early markers of DR in a model of diabetes and hypertension. (AU)

• Processo FAPESP: 05/58189-5 - A hipertensão arterial acentua a neurodegeneração retiniana na patogênese da retinopatia diabética? Possível papel da hipertensão na exacerbação da RD
• Beneficiário: Jacqueline Mendonça Lopes de Faria
• Modalidade de apoio: Auxílio à Pesquisa - Regular
• Processo FAPESP: 08/54068-7 - E possível prevenir os efeitos tóxicos iniciais da hiperglicemia em retina de animais experimentalmente diabéticos através de tratamento antioxidante com tempol, um mimético da superóxido dismutase?
• Beneficiário: Jacqueline Mendonça Lopes de Faria
• Modalidade de apoio: Auxílio à Pesquisa - Regular